Hayashi Masamichi, Kobayashi Daigo, Takami Hideki, Inokawa Yoshikuni, Tanaka Nobutake, Kurimoto Keisuke, Nakanishi Koki, Umeda Shinichi, Shimizu Dai, Hattori Norifumi, Kanda Mitsuro, Tanaka Chie, Nakayama Goro, Kodera Yasuhiro
Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nutr Cancer. 2023;75(5):1330-1339. doi: 10.1080/01635581.2023.2191384. Epub 2023 Mar 24.
The pretreatment albumin-globulin ratio (AGR) is a frequently used inflammation-associated factor that has been reported to have associations with the survival outcomes of various malignancies.
We retrospectively analyzed 162 patients with pancreatic cancer who underwent preoperative treatment followed by curative surgery at Nagoya University Hospital between April 2010 and December 2020. Representative nutritional status indicators of neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), prognostic nutritional index (PNI), and albumin-globulin ratio (AGR) were calculated for each case.
Among pretreatment blood examination parameters, only AGR (cutoff: 1.33) showed a significant difference in overall survival time (OS) and progression-free survival time (PFS) from the beginning of the preoperative treatment. Median PFS was 22.3 mo, in high AGR cases and 17.1 mo, in low AGR cases ( = 0.019). Median OS was 48.7 mo, in high AGR cases and 32.9 mo, in low AGR cases ( = 0.043).
High pretreatment AGR may be a favorable prognostic factor for pancreatic cancer patients who received preoperative multimodal therapy followed by curative cancer resection. It may imply that nutritional status and inflammation control before the multimodal treatment affect the survival outcomes of pancreatic cancer cases and needs to be optimized.
治疗前白蛋白与球蛋白比值(AGR)是一种常用的炎症相关因子,据报道与各种恶性肿瘤的生存结果相关。
我们回顾性分析了2010年4月至2020年12月在名古屋大学医院接受术前治疗并随后进行根治性手术的162例胰腺癌患者。计算每个病例的中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)、预后营养指数(PNI)和白蛋白与球蛋白比值(AGR)等代表性营养状况指标。
在治疗前血液检查参数中,只有AGR(临界值:1.33)在术前治疗开始后的总生存时间(OS)和无进展生存时间(PFS)方面显示出显著差异。高AGR组的中位PFS为22.3个月,低AGR组为17.1个月(P = 0.019)。高AGR组的中位OS为48.7个月,低AGR组为32.9个月(P = 0.043)。
治疗前高AGR可能是接受术前多模式治疗并随后进行根治性癌症切除的胰腺癌患者的一个良好预后因素。这可能意味着多模式治疗前的营养状况和炎症控制会影响胰腺癌病例的生存结果,需要进行优化。